Chemical modifications of RNA influence the micellar assembly stability and intracellular distribution of polycation/RNA complexes
Source abstract
Abstract
RNA molecules play a crucial role in regulating genetic information within cells and have increasingly emerged as a promising class of therapeutic agents for a wide range of diseases. The delivery of RNA to intracellular targets remains a pivotal challenge in advancing RNA-based therapeutics. Current research on RNA delivery has primarily concentrated on the design of delivery carriers and chemical modification of RNA. However, the influence of RNA structural characteristics, particularly chemical modifications, on the assembly properties and intracellular fate of cationic carrier/RNA complexes has been relatively overlooked. Hence, we systematically investigated how chemical modification of RNA influenced the micellar assembly and delivery properties of polycation/RNA complexes, using a cationic polymer (TPE-PEG2K-8R, TP8R) as a model carrier. Nine chemical modifications of RNA significantly altered the assembly, cellular uptake efficiency, and subcellular distribution patterns of polycation/RNA complexes by modulating interfacial interactions. Crucially, using anti-miR-21 as a therapeutic model, we have demonstrated that hydrophobic modifications (e.g., Cy5) induced mitochondrial uptake of the cargo, thus rendering it therapeutically inactive, while hydrophilic and metabolically stable modifications (e.g., 2'-OMe, PS) were essential for cytosolic delivery. This study is expected to establish RNA interfacial chemistry as a critical design parameter for optimizing nucleic acid delivery systems. STATEMENT OF SIGNIFICANCE: While RNA chemical modifications are widely used to enhance stability, their impact on carrier/RNA assembly remains unexplored. This study reveals RNA chemical modifications as pivotal regulators of polycation/RNA complex assembly and intracellular fate. Key findings reveal that: (1) The conformational flexibility of nucleic acids may lead to structural distortions, which could potentially affect the assembly of multimolecular complexes. (2) Nine common chemical modifications of RNA dramatically influenced the assembly structures, binding energies, cellular uptake, and intracellular distribution of complexes. (3) Determining the precise assembly and delivery efficacy of each RNA modification is critical for advancing RNA therapies. This study bridges the gap between RNA chemistry and biomaterials engineering, providing new insights that could guide the rational design of more effective and tunable RNA delivery platforms.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · RNA Research and Splicing · RNA and protein synthesis mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (62)
Show source-provided references
1. RNA therapy10.1038/s12276-023-01051-8 ↗
2. Emerging mRNA technologies: delivery strategies and biomedical applications10.1039/D1CS00617G ↗
3. Programmable RNA base editing via targeted modifications10.1038/s41589-023-01531-y ↗
4. Paving the road for RNA therapeutics10.1016/j.tips.2020.08.004 ↗
5. Recent progress in non-native nucleic acid modifications10.1039/D0CS01430C ↗
6. Elucidating the nanostructure of small interfering RNA-loaded lipidoid-polymer hybrid nanoparticles10.1016/j.jcis.2022.11.141 ↗
7. Self-assembly of siRNA/PEG- b -catiomer at integer molar ratio into 100 nm-sized vesicular polyion complexes (siRNAsomes) for RNAi and codelivery of cargo macromolecules10.1021/jacs.8b13641 ↗
8. Lipid nanoparticles–from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement10.1021/acsnano.1c04996 ↗
9. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy10.1002/adma.202303261 ↗
10. PEGylated nanoparticles for biological and pharmaceutical applications10.1016/S0169-409X(02)00226-0 ↗
11. Polymeric nanocarriers with controlled chain flexibility boost mRNA delivery in vivo through enhanced structural fastening
12. Block catiomer with flexible cationic segment enhances complexation with siRNA and the delivery performance in vitro10.1080/14686996.2021.1976055 ↗
13. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics10.1038/s41565-021-00858-8 ↗
14. How can we use the endocytosis pathways to design nanoparticle drug-delivery vehicles to target cancer cells over healthy cells?10.1039/D1CS00707F ↗
15. Chemistry, structure and function of approved oligonucleotide therapeutics10.1093/nar/gkad067 ↗
16. Chemically modified platforms for better RNA therapeutics10.1021/acs.chemrev.3c00611 ↗
17. Advances in COVID-19 mRNA vaccine development10.1038/s41392-022-00950-y ↗
18. Patisiran: first global approval10.1007/s40265-018-0983-6 ↗
19. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness10.1038/s41586-020-2622-0 ↗
20. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses10.1038/s41586-020-2814-7 ↗
21. Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines10.1021/acscentsci.1c00197 ↗
22. The chemical evolution of oligonucleotide therapies of clinical utility10.1038/nbt.3765 ↗
23. Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: getting the message across10.1016/j.addr.2021.113900 ↗
24. Influence of RNA strand rigidity on polyion complex formation with block catiomers10.1002/marc.201500661 ↗
25. N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting10.1038/s41586-023-06800-3 ↗
26. Rotatable aggregation-induced-emission/aggregation-caused-quenching ratio strategy for real-time tracking nanoparticle dynamics10.1002/adfm.201910348 ↗
27. Advances in the delivery of RNA therapeutics: from concept to clinical reality10.1186/s13073-017-0450-0 ↗
28. Electrostatic adsorption of polyanions onto lipid nanoparticles controls uptake, trafficking, and transfection of RNA and DNA therapies10.1073/pnas.2307809121 ↗
29. A crosslinked nucleic acid nanogel for effective siRNA delivery and antitumor therapy10.1002/anie.201711242 ↗
30. Polymeric delivery of therapeutic nucleic acids10.1021/acs.chemrev.0c00997 ↗
31. Flexibility of nucleic acids: from DNA to RNA10.1088/1674-1056/25/1/018703 ↗
32. Elucidating structural configuration of lipid assemblies for mRNA delivery systems10.1021/acsnano.4c00587 ↗
33. Regulating the proximity effect of heterocycle-containing AIEgens10.1038/s41467-023-39479-1 ↗
34. Non canonical genetic material10.1016/j.copbio.2018.12.001 ↗
35. Polyamines promote xenobiotic nucleic acid synthesis by modified thermophilic polymerase mutants10.1039/D4CB00017J ↗
36. From polymerase engineering to semi-synthetic life: artificial expansion of the central dogma10.1039/D2CB00116K ↗
37. Structure-activity relationships of cytotoxic cholesterol-modified DNA duplexes10.1021/jm00022a025 ↗
38. Live-cell imaging of human apurinic/apyrimidinic endonuclease 1 in the nucleus and nucleolus using a chaperone@DNA probe10.1093/nar/gkae202 ↗
39. A PD-L1 antibody-conjugated PAMAM dendrimer nanosystem for simultaneously inhibiting glycolysis and promoting immune response in fighting breast cancer10.1002/adma.202370296 ↗
40. The role of lipid components in lipid nanoparticles for vaccines and gene therapy10.1016/j.addr.2022.114416 ↗
41. Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes10.1002/adma.201606944 ↗
42. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability10.1038/s41541-023-00751-6 ↗
43. Dyett · Nat. Commun. · 2019 · 10 · 449210.1038/s41467-019-12508-8 ↗
44. Ionizable lipid nanoparticles for mRNA delivery: internal self-assembled inverse mesophase structure and endosomal escape10.1021/acs.accounts.5c00522 ↗
45. Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines10.1016/j.jconrel.2021.08.029 ↗
46. Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm10.1073/pnas.2301067120 ↗
47. A microRNA expression signature of human solid tumors defines cancer gene targets10.1073/pnas.0510565103 ↗
48. MicroRNA gene expression deregulation in human breast cancer10.1158/0008-5472.CAN-05-1783 ↗
49. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer10.1053/j.gastro.2007.05.022 ↗
50. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN10.1007/s11010-012-1443-3 ↗
51. Improved targeting of miRNA with antisense oligonucleotides10.1093/nar/gkl183 ↗
52. Rational design of DNA hydrogels based on molecular dynamics of polymers
53. Nucleic acid drugs: recent progress and future perspectives10.1038/s41392-024-02035-4 ↗
54. Degradable double hydrophilic block copolymers and tripartite polyionic complex micelles thereof for small interfering ribonucleic acids (siRNA) delivery10.1016/j.jcis.2020.07.057 ↗
55. Amphiphilic dendrimer vectors for RNA delivery: state-of-the-art and future perspective10.1021/accountsmr.1c00272 ↗
56. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing10.1038/s41587-023-01679-x ↗
57. Phenyl ring dynamics in a tetraphenylethylene-bridged metal–organic framework: Implications for the mechanism of aggregation-induced emission10.1021/ja306042w ↗
58. Aggregation-induced emission: together we shine, united we soar!10.1021/acs.chemrev.5b00263 ↗
59. Dual-targeted siRubicon delivery strategy triggers hepatocellular lipophagy for mitigating liver steatosis10.1038/s41467-025-61965-x ↗
60. Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH10.1126/sciadv.adx2681 ↗
61. Cargo-selective and adaptive delivery of nucleic acid therapeutics by bola-amphiphilic dendrimers
62. Understanding biophysicochemical interactions at the nano–bio interface10.1038/nmat2442 ↗